Rivaroxaben Tablet

RIVAROOT-10

Rivaroxaban 10 mg Tablets

Division: DIABGLYM

Composition

Each film-coated tablet contains:

Rivaroxaban IP — 10 mg

Excipients — q.s.

Colour: Approved colour used

Dosage form: Film-coated oral tablet

Product Description

RIVAROOT-10 contains Rivaroxaban 10 mg, a direct oral anticoagulant (DOAC) formulated for the prevention of venous thromboembolic disorders and long-term thromboembolic risk reduction. Rivaroxaban is a highly selective direct Factor Xa inhibitor that helps prevent blood clot formation by interrupting the coagulation cascade, thereby reducing the risk of deep vein thrombosis (DVT), pulmonary embolism (PE), and recurrent thromboembolic events.

Rivaroxaban 10 mg is widely prescribed in cardiology, orthopedics, vascular medicine, and internal medicine for thromboprophylaxis following hip and knee replacement surgery, prevention of recurrent venous thromboembolism, and selected patients requiring long-term anticoagulation therapy. It provides effective anticoagulation with predictable pharmacokinetics and does not require routine INR monitoring in most patients.

RIVAROOT-10 is particularly beneficial for patients undergoing major orthopedic surgery, individuals with previous venous thromboembolism, patients requiring extended thromboprophylaxis, and those requiring convenient once-daily oral anticoagulant therapy.

Technical Knowledge of Rivaroxaban

Rivaroxaban selectively and directly inhibits Factor Xa, a key enzyme in the coagulation cascade responsible for the conversion of prothrombin to thrombin. By reducing thrombin generation, Rivaroxaban prevents fibrin clot formation and thrombus development without directly affecting platelet function.

Rivaroxaban has rapid oral absorption, predictable anticoagulant activity, and a relatively short onset of action. It provides consistent anticoagulation with fixed dosing regimens and has fewer dietary interactions compared with vitamin K antagonists.

Mechanism of Action

Rivaroxaban directly inhibits Factor Xa, reduces thrombin generation, prevents fibrin clot formation, inhibits thrombus development, and reduces the risk of venous thromboembolic events.

Key Benefits

Effective prevention of deep vein thrombosis

Prevents pulmonary embolism

Reduces the risk of recurrent venous thromboembolism

Provides postoperative thromboprophylaxis

Predictable anticoagulant activity

No routine INR monitoring required in most patients

Convenient once-daily oral dosing

Suitable for extended anticoagulation under medical supervision

Clinical Applications

RIVAROOT-10 is commonly prescribed for prevention of DVT after hip replacement surgery, prevention of DVT after knee replacement surgery, prevention of pulmonary embolism, extended prevention of recurrent DVT and PE, postoperative thromboprophylaxis, and long-term venous thromboembolic prevention.

Facts About Rivaroxaban

Rivaroxaban is one of the most extensively studied direct oral anticoagulants and has strong clinical evidence supporting venous thromboembolism prevention and treatment. The 10 mg strength is widely used for postoperative thromboprophylaxis and extended prevention of recurrent thromboembolic events. Direct Factor Xa inhibition provides effective anticoagulation with a lower burden of monitoring compared with traditional vitamin K antagonists.

Key Facts

Direct oral anticoagulant (DOAC)

Selective Factor Xa inhibitor

Rivaroxaban 10 mg for thromboprophylaxis and VTE prevention

Effective in DVT and PE prevention

Predictable anticoagulant profile with fixed dosing

Evidence-based thromboembolic prevention therapy

Quality-assured pharmaceutical formulation

PCD Pharma Franchise Opportunity

RIVAROOT-10 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Orthopedic Franchise, and Vascular Medicine Franchise across India. The increasing prevalence of venous thromboembolism, orthopedic surgeries, cardiovascular disease, and thromboembolic disorders creates strong prescription demand and long-term market potential for this formulation.

Why Choose RIVAROOT-10 for PCD Pharma Franchise?

High prescription potential

Strong physician and specialist acceptance

Attractive monopoly franchise opportunity

Competitive pricing

Promotional support available

Visual aids and marketing inputs

Consistent product quality

Excellent repeat business potential

Third Party Manufacturing

Chemsroot Pharmaceutical offers Third Party Manufacturing of Rivaroxaban 10 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.

Our Third Party Manufacturing Services Include

Private label manufacturing

Contract manufacturing

Custom brand manufacturing

Loan license manufacturing

DCGI-compliant production

GMP-certified manufacturing

Batch manufacturing documentation

Product registration support

Customized packaging and artwork

Monopoly franchise packaging

Bulk manufacturing capability

Manufacturing Features

Pharmaceutical-grade raw materials

IP/BP/USP quality standards

In-process quality control

Finished product testing

Stability-oriented formulation

Moisture-controlled tablet manufacturing

Blister and Alu-Alu packaging options

RIVAROOT-10 from DIABGLYM combines effective anticoagulation, comprehensive thromboembolic protection, evidence-based vascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, orthopedic surgeons, vascular specialists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and advanced Rivaroxaban formulation.